The First Clinical Medical College, Nanjing Medical University, Nanjing, China.
Gene. 2013 Dec 10;532(1):94-9. doi: 10.1016/j.gene.2013.09.050. Epub 2013 Sep 23.
The C3435T (rs1045642) polymorphism, located in multi-drug resistance gene 1 (MDR1), has demonstrated its role in decreasing the P-gp activity level which is related to the carcinogenesis. Many published studies have evaluated the association between the MDR1 C3435T polymorphism and breast cancer risk. However, the results remain conflicting rather than conclusive. To derive a more precise estimation of the association between MDR1 C3435T polymorphism and risk of breast cancer, we performed a meta-analysis comprised of 10 case-control studies, including 5282 breast cancer cases and 7703 controls. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to evaluate the strength of the association. The overall results indicated that the variant genotypes were associated with a significantly increased risk of breast cancer (TT versus CC: OR=1.45, 95% CI=1.14-1.30, TT versus CT/CC: OR=1.13, 95% CI=1.04-1.23, TT/CT versus CC: OR=1.22, 95% CI=1.02-1.46). Our results suggest that the MDR1 C3435T polymorphism may contribute to individual susceptibility to breast cancer.
C3435T(rs1045642) 多态性位于多药耐药基因 1 (MDR1) 中，已证明其可降低与致癌作用相关的 P-糖蛋白活性水平。许多已发表的研究评估了 MDR1 C3435T 多态性与乳腺癌风险之间的关联。然而，结果仍然存在争议，而不是结论性的。为了更准确地评估 MDR1 C3435T 多态性与乳腺癌风险之间的关联，我们进行了一项荟萃分析，包括 10 项病例对照研究，共包括 5282 例乳腺癌病例和 7703 例对照。比值比 (OR) 和 95%置信区间 (CI) 用于评估关联的强度。总体结果表明，变异基因型与乳腺癌风险显著增加相关 (TT 与 CC：OR=1.45，95%CI=1.14-1.30，TT 与 CT/CC：OR=1.13，95%CI=1.04-1.23，TT/CT 与 CC：OR=1.22，95%CI=1.02-1.46)。我们的结果表明，MDR1 C3435T 多态性可能导致个体易患乳腺癌。
